Certara (NASDAQ:CERT) is a leading provider of model-informed drug development (MIDD) solutions aimed at optimizing the research, development and regulatory approval of therapeutics. The company’s offerings combine advanced computational modeling and simulation technologies with scientific expertise to streamline decision-making across the drug development lifecycle. Its platforms enable pharmaceutical and biotechnology firms to predict drug behavior, design efficient clinical trials and prepare robust regulatory submissions.
The company’s core products include pharmacokinetic and pharmacodynamic modeling tools, physiologically based pharmacokinetic (PBPK) simulation software and trial‐design optimization applications. These software suites are complemented by a range of advisory services in areas such as regulatory strategy, biomarker analysis and real‐world evidence. By integrating quantitative modeling with domain-specific knowledge, Certara helps clients reduce development timelines, manage risk and improve the probability of clinical success.
Founded in 1985 and headquartered in Princeton, New Jersey, Certara has grown through a series of strategic acquisitions and organic investments. The company’s global footprint spans North America, Europe and the Asia‐Pacific region, with offices and research centers established to support local regulatory requirements and scientific collaboration. Over the years, Certara has merged complementary firms to enhance its technological capabilities, including additions in biomarker sciences, bioinformatics and clinical trial simulation.
Certara is led by President and Chief Executive Officer Joseph H. Cleland, who oversees a management team with deep experience in pharmaceutical sciences, engineering and regulatory affairs. Under this leadership, the company continues to expand its modeling and simulation platform, invest in artificial intelligence‐driven analytics and forge partnerships with industry stakeholders to advance the adoption of MIDD across the biopharmaceutical sector.
